NCT02523040 2025-12-10
Lenalidomide for Adult Histiocyte Disorders
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT01057121 2022-02-08
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed